Prognostic and clinicopathological value of fibrinogen-to-albumin ratio in non-small cell lung cancer: a meta-analysis

Table 3 Subgroup analysis of the prognostic value of FAR for PFS in patients with NSCLC

Subgroups	No. of studies	No. of patients	Effects model	HR (95%CI)	p	Heterogeneity I²(%) Ph		Meta-regression p value
Total	5	1344	Fixed	1.50(1.29–1.74)	< 0.001	37.5	0.171
Sample size								0.752
< 270	3	545	Random	1.51(1.10–2.07)	0.010	51.3	0.129
≥ 270	2	799	Fixed	1.79(1.36–2.35)	< 0.001	0	0.974
TNM stage								0.306
I-III	1	529	-	1.78(1.27–2.50)	0.001	-	-
III-IV	3	621	Random	1.65(1.11–2.40)	0.013	60.6	0.079
I-IV	1	194	-	1.50(1.03–2.17)	0.034	-	-
Treatment								0.833
Surgical resection	1	529	-	1.78(1.27–2.50)	0.001	-	-
Chemotherapy	2	530	Fixed	1.35(1.12–1.64)	0.002	41.4	0.191
Others	2	285	Random	1.85(1.07–3.20)	0.028	51.5	0.151
Cut-off value								0.493
< 0.120	3	983	Fixed	1.42(1.21–1.67)	< 0.001	27.5	0.252
≥ 0.120	2	361	Fixed	2.03(1.38-3.00)	< 0.001	0	0.356
Survival analysis								0.278
Univariate	1	260	-	1.28(1.03–1.58)	0.023	-	-
Multivariate	4	1084	Fixed	1.75(1.42–2.16)	< 0.001	0	0.549

FAR, fibrinogen-to-albumin ratio; NSCLC, non-small cell lung cancer; PFS, progression-free survival; ROC, receiver operating characteristic; TNM, tumor-node-metastasis

ISSN: 1477-7819